Pioglitazone

Generic Name
Pioglitazone
Brand Names
Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
Drug Type
Small Molecule
Chemical Formula
C19H20N2O3S
CAS Number
111025-46-8
Unique Ingredient Identifier
X4OV71U42S
Background

Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medications, which also includes rosiglitazone and troglitazone, exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis.

Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.

Indication

Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.

Associated Conditions
Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
Associated Therapies
-

Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-07-02
Last Posted Date
2012-02-03
Lead Sponsor
Takeda
Target Recruit Count
156
Registration Number
NCT00708175

Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)

First Posted Date
2008-06-10
Last Posted Date
2019-09-09
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
37
Registration Number
NCT00694759
Locations
🇺🇸

Oregon Health & Science University, Portland, Oregon, United States

Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2008-06-04
Last Posted Date
2015-05-29
Lead Sponsor
University of Ulm
Target Recruit Count
219
Registration Number
NCT00690118
Locations
🇩🇪

Department of Neurology and Center for Palliative Medicine, University of Munich, Muenchen, Bayern, Germany

🇩🇪

Department of Neurology, University of Goettingen, Goettingen, Niedersachsen, Germany

🇩🇪

Department of Neurology, University of Halle-Wittenberg, Halle/Saale, Sachsen-Anhalt, Germany

and more 12 locations

Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)

First Posted Date
2008-05-21
Last Posted Date
2008-05-21
Lead Sponsor
Govind Ballabh Pant Hospital
Target Recruit Count
20
Registration Number
NCT00681733
Locations
🇮🇳

Dr. Barjesh Chander Sharma, New Delhi, India

Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-05-13
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
29
Registration Number
NCT00676260

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

First Posted Date
2008-05-13
Last Posted Date
2015-04-09
Lead Sponsor
AstraZeneca
Target Recruit Count
820
Registration Number
NCT00676338
Locations
🇬🇧

Research Site, Swansea, United Kingdom

🇮🇱

Research SIte, Tel-Hashomer, Israel

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-05-06
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
305
Registration Number
NCT00672919

Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome

First Posted Date
2008-05-05
Last Posted Date
2017-01-26
Lead Sponsor
Joseph Calabrese, MD
Target Recruit Count
23
Registration Number
NCT00671515
Locations
🇺🇸

University Hospitals Cleveland Medical Center - Mood Disorders Program, Cleveland, Ohio, United States

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

First Posted Date
2008-04-23
Last Posted Date
2018-10-12
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
19
Registration Number
NCT00665353
Locations
🇺🇸

Ucsf Aids Crs (801), San Francisco, California, United States

🇺🇸

Northwestern University CRS (2701), Chicago, Illinois, United States

🇺🇸

New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477), Newark, New Jersey, United States

and more 5 locations

Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome

First Posted Date
2008-04-11
Last Posted Date
2013-08-28
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
24
Registration Number
NCT00656851
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

© Copyright 2024. All Rights Reserved by MedPath